Neurocrine names Eiry W. Roberts Chief Medical Officer; Sanjay Keswani exits under mutual agreement

NEUROCRINE BIOSCIENCES INC

Eiry W. Roberts, M.D. appointed Chief Medical Officer effective September 28, 2026, succeeding Sanjay Keswani, M.D.
Keswani and the Board mutually agreed his CMO service terminated September 25, 2026; he receives severance under Section 4.1 of the Executive Severance Plan.
Roberts will earn a base salary of $825,000 and a target annual cash bonus equal to 60% of 2026 base pay earned.
Equity grants: options target ~$625,000 vesting monthly over four years; RSUs ~$250,000 and performance RSUs ~$375,000 vesting annually over four years.
Grants auto-issue two business days after the first 10-Q following the transition date; Employment Agreement to be filed with the Q3 2026 10-Q.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.